JAK Inhibitors: Are All Promises Fulfilled?

---

Samantha C. Shapiro, MD, is an academic rheumatologist and an affiliate faculty member of the Dell Medical School at the University of Texas at Austin. She is also a member of the ACR Insurance Subcommittee.

References

1. Taylor PC, Fautrel B, Piette Y, et al. Physicians’ reasons for prescribing Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis, and associated alignment between physicians and patients in a real-world clinical setting [abstract]. Arthritis Rheumatol. 2021:73(suppl 10).
2. Matsuno H. Treatment of rheumatoid arthritis with biological agents. In: Innovative Rheumatology, ed. Matsuno H. London: IntechOpen. 2013.
3. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495–507.
4. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet. 2013 Feb 9;381(9865):451–460.
5. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017 Feb 16;376(7):652–662.
6. Flendrie M, Creemers MCW, Welsing PMJ, et al. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62(suppl 2):ii30–33.
7. Pope J, Keystone E, Jamal S, et al. Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, long-term extension studies up to 8 years [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
8. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: A comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395.
9. Winthrop K, Takeuchi T, Burmester G, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: An updated integrated safety analysis [abstract]. Arthritis Rheumatol. 2020;72(suppl 10).
10. Xie W, Huang Y, Xiao S, et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: Systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019 Aug;78(8):1048–1054.
11. Meissner Y, Albrecht K, Kekow J, et al. Risk of cardiovascular events under Janus kinase inhibitors in patients with rheumatoid arthritis: Observational data from the German RABBIT register. Ann Rheum Dis. 2022;81:86–87.
12. Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis. Gastroenterology. 2020 May;158(6):1554–1573.e12.
13. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022 Jan;386(4):316–326.
14. Khosrow-Khavar F, Kim SC, Lee H, et al. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022 Jun;81(6):798–804.
15. Losavio K. FDA requires new boxed warnings on JAK inhibitors, places restrictions on use. The Rheumatologist. 2021 Sep 1.
16. Pfizer. XELJANZ safety review recommendation issued in the European Union. 2022 Jun 9.